Liang Lin

MedicineImmunology and MicrobiologyEconomics, Econometrics and Finance

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma”.

BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple Myeloma

Cancers(2020)10.3390/cancers12061473

N/A

0DataRank · unranked

54 citations

Liang Lin, Lijie Xing, Yuyin Li, Tengteng Yu, Kenneth C. Anderson +2 more

VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo

Blood Cancer Journal(2020)10.1038/s41408-020-00378-z

N/A

0DataRank · unranked

44 citations

Bharat K. R. Chaganty, Liang Lin, Lijie Xing, Boopathy Ramakrishnan, Kenneth Wen +18 more

γ-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation

Blood Cancer Journal(2022)10.1038/s41408-022-00716-3

N/A

0DataRank · unranked

54 citations

Tengteng Yu, Liang Lin, Lijie Xing, Shih‐Feng Cho, Kenneth Wen +9 more

T reg cells drive MYCN-mediated immunosuppression and tumor aggressiveness in high-risk neuroblastoma

bioRxiv (Cold Spring Harbor Laboratory)(2022)10.1101/2022.10.03.510561

N/A

0DataRank · unranked

1 citations

Andrew Lam, Xu Zhang, Satyaki Sengupta, J. Bryan Iorgulescu, Tao Zuo +16 more